Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―― Live and ...

Powerful tool can map gene regulation at single-nucleotide resolution

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy ...
Le Lézard

Cellarity Announces Two Oral Presentations During the 67th American Society of Hematology Annual Meeting

Cellarity, a clinical-stage, biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced acceptance of two oral presentations on ...

2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon

Vertex has enacted or continued several key launches in 2025. These include its new once-daily triple-combination therapy for ...
Yahoo Finance

Genetix Biotherapeutics to Present Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting

Details regarding the oral presentation can be found below. Abstract Title: Accelerating Access to Gene Therapy: Lessons from Commercial Implementation in Sickle Cell Disease and Transfusion-Dependent ...